Degrading proteins, making medicines
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines that reprogram ubiquitin ligases to eliminate disease-driving proteins previously considered undruggable. The company's proprietary platform integrates MGD chemistry, AI, structural biology, and proteomics to advance programs targeting cancer and other serious diseases.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2021
Mar 2021
May 2020
Create a free account to see which investors have funded this company.
Create Free Account
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
